SI2593128T1 - Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures - Google Patents
Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures Download PDFInfo
- Publication number
- SI2593128T1 SI2593128T1 SI201131461T SI201131461T SI2593128T1 SI 2593128 T1 SI2593128 T1 SI 2593128T1 SI 201131461 T SI201131461 T SI 201131461T SI 201131461 T SI201131461 T SI 201131461T SI 2593128 T1 SI2593128 T1 SI 2593128T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody
- kaderin
- disorder
- protein
- mammalian
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 4
- 239000000203 mixture Substances 0.000 title claims abstract 3
- 230000008685 targeting Effects 0.000 title claims 2
- 102100024155 Cadherin-11 Human genes 0.000 title abstract 4
- 108010000953 osteoblast cadherin Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 11
- 208000035475 disorder Diseases 0.000 claims abstract 8
- 230000001404 mediated effect Effects 0.000 claims abstract 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract 4
- 208000012659 Joint disease Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 230000004761 fibrosis Effects 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 239000003435 antirheumatic agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000029816 Collagenase Human genes 0.000 claims 1
- 108060005980 Collagenase Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 229960002424 collagenase Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36469810P | 2010-07-15 | 2010-07-15 | |
| EP11741717.0A EP2593128B1 (en) | 2010-07-15 | 2011-07-15 | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| PCT/US2011/044172 WO2012009631A1 (en) | 2010-07-15 | 2011-07-15 | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2593128T1 true SI2593128T1 (en) | 2018-08-31 |
Family
ID=44630044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131461T SI2593128T1 (en) | 2010-07-15 | 2011-07-15 | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8940300B2 (enExample) |
| EP (2) | EP2593128B1 (enExample) |
| JP (2) | JP5886283B2 (enExample) |
| KR (1) | KR101695056B1 (enExample) |
| CN (2) | CN103153331B (enExample) |
| AU (1) | AU2011279044B2 (enExample) |
| BR (1) | BR112013001062A2 (enExample) |
| CA (1) | CA2805112A1 (enExample) |
| DK (1) | DK2593128T3 (enExample) |
| ES (1) | ES2665317T3 (enExample) |
| HR (1) | HRP20180563T1 (enExample) |
| HU (1) | HUE038000T2 (enExample) |
| IL (2) | IL224186A (enExample) |
| LT (1) | LT2593128T (enExample) |
| MX (1) | MX343376B (enExample) |
| NO (1) | NO2593128T3 (enExample) |
| PT (1) | PT2593128T (enExample) |
| RS (1) | RS57215B1 (enExample) |
| SG (1) | SG187097A1 (enExample) |
| SI (1) | SI2593128T1 (enExample) |
| WO (1) | WO2012009631A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3181588A1 (en) | 2008-01-11 | 2017-06-21 | Adheron Therapeutics, Inc. | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| EP2593128B1 (en) | 2010-07-15 | 2018-01-10 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| FI3378535T3 (fi) | 2011-10-28 | 2023-04-12 | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| EP2830659A1 (en) * | 2012-03-27 | 2015-02-04 | Novartis AG | Treatment of fibrosis |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP2016515524A (ja) * | 2013-03-15 | 2016-05-30 | アッヴィ バイオテクノロジー リミテッド | 抗ｃｄ２５抗体およびそれらの使用 |
| AU2014233503A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2016100301A1 (en) * | 2014-12-15 | 2016-06-23 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders |
| US11207419B2 (en) * | 2016-01-09 | 2021-12-28 | Arbele Limited | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
| MX2021001268A (es) * | 2018-08-01 | 2021-09-08 | Imcheck Therapeutics Sas | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. |
| CN113072633B (zh) * | 2021-04-21 | 2022-11-15 | 湖北医药学院 | Cdh11截短型变体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | TRYPTOPHANE GENERATING MICROORGANISM. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DK0786469T3 (da) | 1990-06-11 | 2006-07-10 | Gilead Sciences Inc | Nukleinsyreligander |
| EP0835939B8 (de) | 1990-06-28 | 2006-01-11 | Sanofi-Aventis Deutschland GmbH | Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| JP3560252B2 (ja) * | 1992-08-28 | 2004-09-02 | アベンティス ファーマ株式会社 | 骨関連カドヘリン様タンパク質およびその製造法 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
| US6638911B1 (en) | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| AU759144B2 (en) | 1998-05-05 | 2003-04-03 | Adherex Technologies Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US6787136B1 (en) | 1999-09-03 | 2004-09-07 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| WO2001017557A1 (en) * | 1999-09-03 | 2001-03-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| EP1560850A2 (en) | 2002-11-14 | 2005-08-10 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| WO2006089397A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| EP3181588A1 (en) | 2008-01-11 | 2017-06-21 | Adheron Therapeutics, Inc. | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| US20100322926A1 (en) * | 2008-02-11 | 2010-12-23 | Novartis Ag | Methods of using cadherin 11 (cdh11) antagonists |
| EP2593128B1 (en) | 2010-07-15 | 2018-01-10 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
-
2011
- 2011-07-15 EP EP11741717.0A patent/EP2593128B1/en active Active
- 2011-07-15 WO PCT/US2011/044172 patent/WO2012009631A1/en not_active Ceased
- 2011-07-15 NO NO11741717A patent/NO2593128T3/no unknown
- 2011-07-15 HR HRP20180563TT patent/HRP20180563T1/hr unknown
- 2011-07-15 DK DK11741717.0T patent/DK2593128T3/en active
- 2011-07-15 ES ES11741717.0T patent/ES2665317T3/es active Active
- 2011-07-15 PT PT117417170T patent/PT2593128T/pt unknown
- 2011-07-15 AU AU2011279044A patent/AU2011279044B2/en not_active Ceased
- 2011-07-15 JP JP2013519849A patent/JP5886283B2/ja not_active Expired - Fee Related
- 2011-07-15 CN CN201180042808.0A patent/CN103153331B/zh not_active Expired - Fee Related
- 2011-07-15 KR KR1020137003804A patent/KR101695056B1/ko not_active Expired - Fee Related
- 2011-07-15 LT LTEP11741717.0T patent/LT2593128T/lt unknown
- 2011-07-15 EP EP17203400.1A patent/EP3345925A3/en not_active Withdrawn
- 2011-07-15 SI SI201131461T patent/SI2593128T1/en unknown
- 2011-07-15 SG SG2013003454A patent/SG187097A1/en unknown
- 2011-07-15 CN CN201710140463.1A patent/CN107090039A/zh active Pending
- 2011-07-15 BR BR112013001062A patent/BR112013001062A2/pt not_active Application Discontinuation
- 2011-07-15 US US13/810,018 patent/US8940300B2/en active Active
- 2011-07-15 CA CA2805112A patent/CA2805112A1/en not_active Abandoned
- 2011-07-15 HU HUE11741717A patent/HUE038000T2/hu unknown
- 2011-07-15 RS RS20180419A patent/RS57215B1/sr unknown
- 2011-07-15 MX MX2013000434A patent/MX343376B/es active IP Right Grant
-
2013
- 2013-01-13 IL IL224186A patent/IL224186A/en active IP Right Grant
-
2015
- 2015-01-26 US US14/605,543 patent/US20150132305A1/en not_active Abandoned
-
2016
- 2016-01-26 IL IL243775A patent/IL243775A0/en unknown
- 2016-02-10 JP JP2016023490A patent/JP6223483B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2593128T1 (en) | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures | |
| US20230192831A1 (en) | Human Antibodies to GREM1 | |
| CN105829349B (zh) | 肽嵌合抗原受体t细胞开关和其用途 | |
| JP7034068B2 (ja) | レプチン受容体を活性化させる抗原結合タンパク質 | |
| JP6302844B2 (ja) | 抗ａｓｉｃ１抗体及びその使用 | |
| JP2011509094A5 (enExample) | ||
| JP2018512157A5 (enExample) | ||
| JP2016512430A (ja) | Ｎａｖ１．７に対するヒト抗体 | |
| JP2014503482A5 (enExample) | ||
| US9783605B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
| JP2017505125A (ja) | Ｐｄ−１に対するヒト抗体 | |
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| JP2013535190A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| RS57291B1 (sr) | Pan-elr+cxc hemokin antitela | |
| JP2019537617A5 (enExample) | ||
| JP2017509649A5 (enExample) | ||
| EP3585806A1 (en) | Immunoconjugates with optimized linkers and orientation | |
| RU2013134983A (ru) | Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области | |
| JP2024531419A (ja) | 線維性疾患の治療におけるアルファ－エノラーゼアンタゴニストの使用 | |
| US20190225682A1 (en) | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody | |
| US20140178395A1 (en) | Treatment of nephropathy | |
| WO2023061502A1 (zh) | 一种双特异性结合分子 | |
| Pagani | Development and characterisation of phage display-derived antibodies for synovial specific drug delivery in Rheumatoid Arthritis |